BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 12719883)

  • 21. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy.
    Morgan KP; Buie LW; Savage SW
    Ann Pharmacother; 2012 Feb; 46(2):276-81. PubMed ID: 22298599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
    Makimoto G; Ichihara E; Hotta K; Ninomiya K; Oze I; Minami D; Ninomiya T; Kubo T; Ohashi K; Tabata M; Maeda Y; Kiura K
    Acta Med Okayama; 2018 Jun; 72(3):319-323. PubMed ID: 29926012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?
    Ruggiero A; Rizzo D; Trombatore G; Maurizi P; Riccardi R
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):19-26. PubMed ID: 26589789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study.
    Paterna S; Di Pasquale P; Parrinello G; Fornaciari E; Di Gaudio F; Fasullo S; Giammanco M; Sarullo FM; Licata G
    J Am Coll Cardiol; 2005 Jun; 45(12):1997-2003. PubMed ID: 15963399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
    JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
    Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A short outpatient hydration schedule for cisplatin administration.
    Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
    Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the effect of acetazolamide versus mannitol on cisplatin-induced nephrotoxicity, a pilot study.
    El Hamamsy M; Kamal N; Bazan NS; El Haddad M
    Int J Clin Pharm; 2018 Dec; 40(6):1539-1547. PubMed ID: 30167970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity.
    Campbell AB; Kalman SM; Jacobs C
    Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.
    Lagrange JL; Médecin B; Etienne MC; Pivot X; Cassuto-Viguier E; Renée N; Thyss A; Ferrero JM; Otto J; François E; Milano G
    Pharmacotherapy; 1997; 17(6):1246-53. PubMed ID: 9399607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods of reduction of cisplatin nephrotoxicity.
    Walker EM; Gale GR
    Ann Clin Lab Sci; 1981; 11(5):397-410. PubMed ID: 6277229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mannitol for the prevention of cisplatin-induced nephrotoxicity: A retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center.
    Williams RP; Ferlas BW; Morales PC; Kurtzweil AJ
    J Oncol Pharm Pract; 2017 Sep; 23(6):422-428. PubMed ID: 27352615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cisplatin-induced vomiting depends on circadian timing.
    Kobayashi M; To H; Tokue A; Fujimura A; Kobayashi E
    Chronobiol Int; 2001 Sep; 18(5):851-63. PubMed ID: 11763992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cisplatin administration for outpatients with short hydration of less than four hours].
    Hata A; Katakami N; Masuda Y; Kaji R; Fujita S; Iwamori S; Horai A; Takatori K; Ose T; Kitajima N; Mifune Y; Fukae M
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1385-8. PubMed ID: 22996774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
    Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
    Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial.
    van der Voort PH; Boerma EC; Koopmans M; Zandberg M; de Ruiter J; Gerritsen RT; Egbers PH; Kingma WP; Kuiper MA
    Crit Care Med; 2009 Feb; 37(2):533-8. PubMed ID: 19114909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.